🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Meet Muse, our latest AI innovation for drug development—a tool designed to optimize patient recruitment built together w. Sanofi and OpenAI. Muse is an example of how AI systems are becoming capable of performing tasks that once required entire teams or organizations.

Great example of a tangible AI use case in one of the most intractable problem areas - drug development. Congrats Formation Bio

“If we think about all the drug development activities, we think there’s a Muse for everything,” Formation Bio CEO Benjamine Liu said. “This all ladders up to a broader AI R&D scientist.” A bold claim for a big vision from Liu — but a first step here: endpts.com/sanofi-openai-…

In Chinese culture, they call it 'eating bitterness,' Kobe Bryant called it Mamba Mentality. Read my thoughts on why we must embrace this mentality this Chinese New Year. benliu.posthaven.com/happy-chinese-…

AI & Entrepreneurship in 2025: Are one-person billion-dollar businesses possible? Ben Liu Formation Bio Dan Murphy CNBC Kanjun 🐙 Imbue Mitchell Green Lead Edge Capital Sarah Franklin Lattice Richard Socher you.com #AI #startup #WEF25 ow.ly/HvQO50UOYWx

Thrilled to welcome Mikael Dolsten, MD, PhD, former Chief Scientific Officer and President of Pfizer R&D, to Formation Bio to chair our drug picking efforts. As we look to bring together the best of pharma with the best of AI and technology, we are honored to partner with Mikael

As AI transform drug discovery, clinical trials and drug development will be the most consequential bottleneck. Excited to be on this year's CNBC Disruptors list as we look to build this generation's enduring pharma company.

A disruptor in the AI drug discovery space... Formation Bio's Ben Liu explains how his company is using AI in drug development and what's next for a quickly evolving space cnb.cx/4kYrK4X

Thanks CNBC CNBC's Fast Money for having me on!

Congrats to Sanofi and Formation Bio on the start of a great partnership

Enjoyed chatting with the team a16z and Tech Week. Not sure that Art Levinson (now Calico) remembers our call, but his advice left an indelible impact on how we think about mission, values, and cultural inertia.

Excited to share an update at Formation Bio: We’ve added @Imidomics first-in-class anti-CD226 antibody to our pipeline — a Phase 1–ready program for Ulcerative Colitis. Grateful to Fred Craves & Sandy Zweifach for the collaboration and shared vision for the program’s future.